-
1.发明授权
公开(公告)号：US5274076A
公开(公告)日：1993-12-28
申请号：US584003
申请日：1990-09-18
IPC分类号： G01N33/53 , A61K39/00 , A61K39/385 , A61K39/395 , A61K45/08 , A61K51/00 , A61K51/08 , A61K51/10 , A61P35/00 , C07K5/02 , C07K5/033 , C07K5/065 , C07K5/083 , C07K14/00 , C07K16/00 , G01N33/532 , G01N33/574 , G01N33/577 , C07K5/06 , C07C237/20 , C07K5/08 , C07K5/10
CPC分类号： G01N33/5743 , A61K51/088 , A61K51/1093 , C07K5/06078 , C07K5/0806 , G01N33/532 , A61K2123/00
摘要： Derivatives comprising two hydrophilic haptens and an effector group comprising a radioactive isotope or known to be able to be labelled by a radioactive isotope or comprising an active principle or known to be able to bind an active principle, linked by a connecting bridge application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents containing them.
摘要翻译： 包含两个亲水性半抗原的衍生物和包含放射性同位素或已知能够被放射性同位素标记或包含活性成分或已知能够结合活性成分的活性成分的效应基团的效应基团，其通过连接桥应用与诊断和 用于治疗，诊断或治疗试剂盒和含有它们的免疫试剂。
-
公开(公告)号：US09809624B2
公开(公告)日：2017-11-07
申请号：US13384418
申请日：2010-07-16
申请人： Anne Gruaz , Didier Pelaprat , Jacques Barbet , Dirk Tourwe
发明人： Anne Gruaz , Didier Pelaprat , Jacques Barbet , Dirk Tourwe
CPC分类号： C07K7/083 , A61K38/00 , A61K51/08 , A61K51/085 , A61K51/088
摘要： The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
-
公开(公告)号：US06326401B1
公开(公告)日：2001-12-04
申请号：US09225742
申请日：1999-01-06
申请人： Jacques Chauveau , Pascal Meyer , Jacques Barbet , Michel Delaage
发明人： Jacques Chauveau , Pascal Meyer , Jacques Barbet , Michel Delaage
IPC分类号： A61K3122
CPC分类号： A61K47/14 , A61K9/0043 , A61K9/006 , Y10S514/966
摘要： A liquid pharmaceutical formulation for administration by the oro-mucosal route, comprising at least one non-polypeptidic active substance and less than 5% W/W of capryl caproyl macrogol glycerides, process for its preparation and it uses.
摘要翻译： 用于通过粘膜途径施用的液体药物制剂，其包含至少一种非多肽活性物质和小于5％W / W的辛酸甘油基甘露糖苷，其制备及其用途。
-
4.发明授权Process for the identification or determination of proteins and its applications 失效用于鉴定或测定蛋白质及其应用的方法
公开(公告)号：US5449601A
公开(公告)日：1995-09-12
申请号：US61350
申请日：1993-05-17
申请人： Frederic Jean , Jacques Barbet , Michel Delaage
发明人： Frederic Jean , Jacques Barbet , Michel Delaage
IPC分类号： G01N33/53 , G01N33/531 , G01N33/569 , G01N33/68 , G01N33/74 , C12Q1/70
CPC分类号： G01N33/6878 , G01N33/531 , G01N33/56988 , G01N33/6803 , G01N33/74 , Y10S435/974 , Y10T436/25 , Y10T436/25125
摘要： Process for the identification or determination of proteins by producing antibodies with the aid of peptides that are made immunogenic if necessary, and then using the resulting antibodies to determine the proteins of interest, starting with a sample that contains these and which is treated to liberate the said peptides, in which process the said peptide is so chosen that it matches a known amino acid sequence of the said protein and is used as a protein fragment that the protein can be made to release on enzymatic treatment, after which it is synthesized, the invention also relating to the applications of this process for the identification or the determination of proteins.
摘要翻译： 借助于需要制成免疫原性肽的肽产生抗体，然后使用得到的抗体来确定感兴趣的蛋白质，从包含这些蛋白质的样品开始并将其解放出来，从而鉴定或测定蛋白质的方法 所述肽，其中所述肽被选择为使得其与所述蛋白质的已知氨基酸序列匹配，并且用作蛋白质片段，所述蛋白质可以在酶处理时释放，之后合成， 本发明还涉及该方法用于鉴定或测定蛋白质的应用。
-
5.发明申请USE OF MONOCLONAL ANTIBODIES SPECIFIC TO THE O-ACETYLATED FORM OF GD2 GANGLIOSIDE FOR TREATMENT OF CERTAIN CANCERS 有权使用特定于GD2 GANGLIOSO的O-乙酰甲胺治疗某些癌症的单克隆抗体公开(公告)号：US20100150910A1
公开(公告)日：2010-06-17
申请号：US12445071
申请日：2007-10-10
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.
摘要翻译： 本发明涉及仅识别GD2神经节苷脂的O-乙酰化形式或所述抗体的片段的单克隆抗体用于诊断和治疗其中细胞表达O-乙酰化GD2的所述抗体或所述抗体的所述抗体或 所述片段识别由肿瘤细胞表达的O-乙酰化GD2分子，并且不识别在外周神经表面表达的GD2分子，以增加诊断的特异性并降低治疗的毒性。 本发明还涉及有利地用于治疗和诊断细胞表达O-乙酰化GD2的癌症的人造修饰的抗体。
-
6.发明授权Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells 失效用于体内检测和杀死特异性靶细胞的亲和力增强免疫试剂
公开(公告)号：US5256395A
公开(公告)日：1993-10-26
申请号：US96829
申请日：1987-09-10
IPC分类号： G01N33/531 , A61K39/00 , A61K39/395 , A61K47/48 , A61K51/00 , A61K51/10 , A61P35/00 , C07K16/46 , G01N33/48 , G01N33/536 , G01N33/574 , A61K49/02
CPC分类号： A61K51/1093 , A61K47/48438 , A61K2121/00 , A61K2123/00
摘要： Immunological reagents, consisting of a) antibody or fragment conjugates having both an anti-cell specificity and an anti-hapten specificity, and b) synthetic tracers containing at least two hapten sites and at least one site suitable to attach radioactive isotopes, paramagnetic ions, drugs or toxins, are provided. These reagents are capable of binding to target cells in a specific way, and the tracer localizes preferentially on the membrane of antigen-bearing cells, even in the presence of excess antibody conjugate (affinity enhancement). These reagents are usefully employed, either in vitro or in vivo, to detect tumors, metastases, or other tissue injuries, when the synthetic tracer carries radioactive or paramagnetic compounds, and to kill target cells when the synthetic tracer carries radioactive compounds or drugs or toxins.
-
7.发明授权Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for treatment of certain cancers 有权使用特异于O-乙酰化形式的GD2神经节苷脂的单克隆抗体用于治疗某些癌症公开(公告)号：US08951524B2
公开(公告)日：2015-02-10
申请号：US12445071
申请日：2007-10-10
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.
摘要翻译： 本发明涉及仅识别GD2神经节苷脂的O-乙酰化形式或所述抗体的片段的单克隆抗体用于诊断和治疗其中细胞表达O-乙酰化GD2的所述抗体或所述抗体的所述抗体或 所述片段识别由肿瘤细胞表达的O-乙酰化GD2分子，并且不识别在外周神经表面表达的GD2分子，以增加诊断的特异性并降低治疗的毒性。 本发明还涉及有利地用于治疗和诊断细胞表达O-乙酰化GD2的癌症的人造修饰的抗体。
-
8.发明申请NEUROTENSIN ANALOGUES FOR RADIOISOTOPE TARGETING TO NEUROTENSIN RECEPTOR-POSITIVE TUMORS 有权用于神经递质受体阳性肿瘤的放射线照射的神经递质模拟物公开(公告)号：US20120207676A1
公开(公告)日：2012-08-16
申请号：US13384418
申请日：2010-07-16
申请人： Anne Gruaz-Guyon , Didier Pelaprat , Jacques Barbet , Dirk Tourwe
发明人： Anne Gruaz-Guyon , Didier Pelaprat , Jacques Barbet , Dirk Tourwe
IPC分类号： A61K51/08 , G01N33/574 , A61K38/17 , C07K14/47
CPC分类号： C07K7/083 , A61K38/00 , A61K51/08 , A61K51/085 , A61K51/088
摘要： The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adeno-carcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
摘要翻译： 本发明涉及可用于靶向神经降压素受体阳性肿瘤的新型神经降压素类似物或其盐，例如导管胰腺腺癌，外分泌胰腺癌，浸润性导管乳腺癌，结肠腺癌，小细胞肺癌，尤文肉瘤 ，脑膜瘤，成神经管细胞瘤和星形细胞瘤。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.012 秒)